Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation

Oncotarget

Volumn 7, Issue 3, 2016, Pages 2837-2854

  Bahram, Fuad ^a,b,d   Hydbring, Per ^a,e   Tronnersjö, Susanna ^a,f   Zakaria, Siti Mariam ^a   Frings, Oliver ^a   Fahlén, Sara ^a   Nilsson, Helén ^a,g   Goodwin, Jacob ^a   von der Lehr, Natalie ^b,h   Su, Yingtao ^a,i   Lüscher, Bernhard ^c   Castell, Alina ^a   Larsson, Lars Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Moreinx AB   (Sweden)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BIACORE AB   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h NatScience   (Sweden)

ⁱ Anxun International Co Limited   (Hong Kong)

Author keywords

Interferon gamma; Oncogene; The cancer genome atlas; Tumor suppressor gene; Ubiquitin proteasome system

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GAMMA INTERFERON; GLYCOPROTEIN P 15095; JANUS KINASE; MYC PROTEIN; STAT1 PROTEIN; CDK2 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; PROTEASOME; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RAT; SENESCENCE; UBIQUITINATION; ANIMAL; CELL AGING; CELL NUCLEUS; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENE EXPRESSION REGULATION; HELA CELL LINE; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INTERFERON-GAMMA; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84962221857     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6693     Document Type: Article

References (68)

1. Dang CV. Myc on the path to cancer. Cell. 2012; 149:22-35.
2. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008; 22:2755-2766.
3. Larsson LG, Henriksson MA. The yin and yang functions of the myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010; 316:1429-1437.
4. Luscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein myc. Gene. 2012; 494:145-160.
5. Meyer N, Penn LZ. Reflecting on 25 years with myc. Nat Rev Cancer. 2008; 8:976-990.
6. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-myc. Cell. 2012; 151:56-67.
7. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151:68-79.
8. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Faga G, Bianchi V, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014; 511:488-492.
9. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, Roels F, Wustefeld T, Fischer M, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014; 511:483-487.
10. Herkert B, Eilers M. Transcriptional repression: The dark side of myc. Genes Cancer. 2010; 1:580-586. doi: 10.1177/1947601910379012.
11. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463:899-905.
12. Farrell AS, Sears RC. Myc degradation. Cold Spring Harb Perspect Med. 2014; 4.
13. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. C-myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000; 95:2104-2110.
14. Salghetti SE, Kim SY, Tansey WP. Destruction of myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize myc. Embo J. 1999; 18:717-726.
15. Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, SharifiHR, Lilischkis R, Hein N, Wu S, Vervoorts J, Henriksson M, Grandien A, et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:58-63.
16. Lutterbach B, Hann SR. Hierarchical phosphorylation at n-terminal transformation-sensitive sites in c-myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994; 14:5510-5522.
17. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple ras-dependent phosphorylation pathways regulate myc protein stability. Genes Dev. 2000; 14:2501-2514.
18. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature cell biology. 2004; 6:308-318.
19. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. The fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-myc protein degradation. Proc Natl Acad Sci USA. 2004; 101:9085-9090.
20. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI. Phosphorylation-dependent degradation of c-myc is mediated by the f-box protein fbw7. Embo J. 2004; 23:2116-2125.
21. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, Kogel U, Scheffner M, Helin K, et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell. 2005; 123:409-421.
22. Cepeda D, Ng HF, SharifiHR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Vinals F, Bhaskaran N, et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO molecular medicine. 2013; 5:999-1018.
23. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates myc protein stability and activity. Mol Cell. 2003; 11:1177-1188.
24. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, Soderberg O, Kerppola TK, Larsson LG. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Molecular cell. 2003; 11:1189-1200.
25. Hydbring P, Larsson LG. Tipping the balance: Cdk2 enables myc to suppress senescence. Cancer Res. 2010; 70: 6687-6691.
26. Chu IM, Hengst L, Slingerland JM. The cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nature reviews. Cancer. 2008; 8:253-267.
27. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(cip1), p27(kip1) and p57(kip2) cdk inhibitors. Cell Cycle. 2010; 9:2342-2352.
28. Vervoorts J, Luscher B. Post-translational regulation of the tumor suppressor p27(kip1). Cell Mol Life Sci. 2008; 65:3255-3264.
29. Oberg F, Larsson LG, Anton R, Nilsson K. Interferon gamma abrogates the differentiation block in v-myc-expressing u-937 monoblasts. Proc Natl Acad Sci USA. 1991; 88:5567-5571.
30. Tworkowski KA, Salghetti SE, Tansey WP. Stable and unstable pools of myc protein exist in human cells. Oncogene. 2002; 21:8515-8520.
31. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B. Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: Opposite regulation of mad and c-myc. Oncogene. 1994; 9:1247-1252.
32. Hu CD, Chinenov Y, Kerppola TK. Visualization of interactions among bzip and rel family proteins in living cells using bimolecular fluorescence complementation. Mol Cell. 2002; 9:789-798.
33. Arabi A, Wu S, Ridderstrale K, BierhoffH, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg O, Grummt I, Larsson LG, Wright AP. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nature cell biology. 2005; 7:303-310.
34. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and-independent pathways in ifn-gamma-dependent signaling. Trends Immunol. 2002; 23:96-101.
35. Salghetti SE, Kim SY, Tansey WP. Destruction of myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize myc. Embo J. 1999; 18:717-726.
36. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.
37. Vervoorts J, Luscher-FirzlaffJ, Luscher B. The ins and outs of myc regulation by posttranslational mechanisms. J Biol Chem. 2006; 281:34725-34729.
38. Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S, Gallastegui E, Saiz C, Besson A, Pujol MJ, Lopez-Bigas N, Paramio JM, Bigas A, et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene. 2012; 31:4207-4220.
39. Jeon MJ, Yang W, Seo HS, Wang ES, Shin I. Down-regulation of estrogen receptor alpha (eralpha) transcriptional activity by p27 is mediated by inhibition of eralpha nuclear localization and modulation of the eralpha transcriptional complex. Cell Signal. 2012; 24:2249-2258.
40. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, Larsson LG, Hermeking H. The c-myc oncoprotein, the nampt enzyme, the sirt1-inhibitor dbc1, and the sirt1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA. 2012; 109:E187-196.
41. Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ. MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer research. 2013; 73:6504-6515.
42. Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. Sirt1 inactivation evokes antitumor activities in nsclc through the tumor suppressor p27. Mol Cancer Res. 2015; 13:41-49.
43. Cowling VH, Chandriani S, Whitfield ML, Cole MD. A conserved myc protein domain, mbiv, regulates DNA binding, apoptosis, transformation, and g2 arrest. Mol Cell Biol. 2006; 26:4226-4239.
44. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. P27kip1 modulates cell migration through the regulation of rhoa activation. Genes Dev. 2004; 18:862-876.
45. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. Novel p27(kip1) c-terminal scatter domain mediates rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol. 2003; 23:216-228.
46. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001; 20:1688-1702.
47. McArthur GA, Foley KP, Fero ML, Walkley CR, Deans AJ, Roberts JM, Eisenman RN. Mad1 and p27(kip1) cooperate to promote terminal differentiation of granulocytes and to inhibit myc expression and cyclin e-cdk2 activity. Mol Cell Biol. 2002; 22:3014-3023.
48. Hwang HC, Martins CP, Bronkhorst Y, Randel E, Berns A, Fero M, Clurman BE. Identification of oncogenes collaborating with p27kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci USA. 2002; 99:11293-11298.
49. Martins CP, Berns A. Loss of p27(kip1) but not p21(cip1) decreases survival and synergizes with myc in murine lymphomagenesis. Embo J. 2002; 21:3739-3748.
50. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature medicine. 2002; 8:1153-1160.
51. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: An oncogenic function for cdk inhibitors? Nature reviews. Cancer. 2004; 4:948-955.
52. Besson A, Dowdy SF, Roberts JM. Cdk inhibitors: Cell cycle regulators and beyond. Dev Cell. 2008; 14:159-169.
53. Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF. Relocalized p27kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res. 2007; 67:9238-9243.
54. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD. Reduced expression of p27kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat. 1999; 55: 161-167.
55. Oshita F, Kameda Y, Nishio K, Tanaka G, Yamada K, Nomura I, Nakayama H, Noda K. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep. 2000; 7:491-495.
56. Caraballo JM, Acosta JC, Cortes MA, Albajar M, Gomez-Casares MT, Batlle-Lopez A, Cuadrado MA, Onaindia A, Bretones G, Llorca J, Piris MA, Colomer D, Leon J. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget. 2014; 5:4694-4708. doi:10.18632/oncotarget.2100.
57. Kim SS, Meitner P, Konkin TA, Cho YS, Resnick MB, Moss SF. Altered expression of skp2, c-myc and p27 proteins but not mrna after h. Pylori eradication in chronic gastritis. Mod Pathol. 2006; 19:49-58.
58. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 2015.
59. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. Chemical genetics approach to restoring p27kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol. 2010; 8:153.
60. Wu L, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule inhibitors of skp2-mediated p27 degradation. Chem Biol. 2012; 19:1515-1524.
61. Ooi LC, Watanabe N, Futamura Y, Sulaiman SF, Darah I, Osada H. Identification of small molecule inhibitors of p27(kip1) ubiquitination by high-throughput screening. Cancer Sci. 2013; 104:1461-1467.
62. Pavlides SC, Huang KT, Reid DA, Wu L, Blank SV, Mittal K, Guo L, Rothenberg E, Rueda B, Cardozo T, Gold LI. Inhibitors of scf-skp2/cks1 e3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: Therapeutic potential for endometrial cancer. Endocrinology. 2013; 154:4030-4045.
63. Morishita D, Takami M, Yoshikawa S, Katayama R, Sato S, Kukimoto-Niino M, Umehara T, Shirouzu M, Sekimizu K, Yokoyama S, Fujita N. Cell-permeable carboxyl-terminal p27(kip1) peptide exhibits anti-tumor activity by inhibiting pim-1 kinase. J Biol Chem. 2011; 286:2681-2688.
64. Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Pahlman S, Guzhova I, Larsson LG. Combined ifn-gamma and retinoic acid treatment targets the n-myc/max/mad1 network resulting in repression of n-myc target genes in mycn-amplified neuroblastoma cells. Mol Cancer Ther. 2007; 6:2634-2641.
65. Finn OJ. Cancer immunology. N Engl J Med. 2008; 358:2704-2715.
66. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013; 494:361-365.
67. Bahram F, Wu S, Oberg F, Luscher B, Larsson LG. Posttranslational regulation of myc function in response to phorbol ester/interferon-gamma-induced differentiation of v-myc-transformed u-937 monoblasts. Blood. 1999; 93:3900-3912.
68. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nature methods. 2009; 6:239-240.